文献速递慢阻肺

慢阻肺患者血清sfrp5水平与气道炎症及胰岛素抵抗的相关性分析

[Correlation analysis of serum secreted frizzled-related protein 5 levels with airway inflammation and insulin resistance in chronic obstructive pulmonary disease patients].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2017-01-01

研究纳入178例慢阻肺患者与99名健康对照,比较血清sfrp5水平并分析其与胰岛素抵抗、诱导痰炎症因子及肺功能的关系。结果示慢阻肺组sfrp5高于对照组,胰岛素抵抗慢阻肺组sfrp5最低且炎症因子最高、肺功能最差;sfrp5与FEV1/FVC及FEV1占预计值正相关,与ln(HOMA-IR)、TNF-α、IL-6负相关。提示sfrp5可能参与慢阻肺发生发展及胰岛素抵抗影响气道炎症的过程。

要点

  • 慢阻肺患者血清sfrp5水平显著高于健康对照。
  • 合并胰岛素抵抗的慢阻肺患者sfrp5更低、气道炎症更重、气流受限更明显。
  • sfrp5与肺功能正相关、与胰岛素抵抗及诱导痰TNF-α、IL-6负相关。

核心结论

  • sfrp5可能同时与慢阻肺和胰岛素抵抗有关。
  • 胰岛素抵抗可能与气道炎症和气流受限有关。
  • sfrp5可能参与慢阻肺发生发展,并可能是胰岛素抵抗影响气道炎症的关键环节。

研究设计与样本

  • 选取2015年2月至2017年1月呼吸门诊慢阻肺患者178例,同期健康对照99名。
  • 按HOMA-IR≥2.29分为胰岛素抵抗慢阻肺组、非胰岛素抵抗慢阻肺组、单纯性胰岛素抵抗组和正常对照组。
  • 比较各组血清sfrp5、诱导痰炎症因子及肺功能并作相关分析。

主要发现

  • 慢阻肺组血清sfrp5显著高于健康对照组(t=-14.29,P<0.001)。
  • 胰岛素抵抗慢阻肺组sfrp5为(8±3)ng/ml,低于非胰岛素抵抗慢阻肺组(10±5)ng/ml、单纯性胰岛素抵抗组(13±3)ng/ml和正常对照组(14±4)ng/ml(F=35.85,P<0.01)。
  • 胰岛素抵抗慢阻肺组ln(HOMA-IR)、诱导痰TNF-α和IL-6高于其余三组(F值分别为64.968、41.40、64.15,均P<0.01)。
  • 胰岛素抵抗慢阻肺组FEV1/FVC和FEV1占预计值低于其余三组(F值分别为2.481、8.37,均P<0.05)。
  • 血清sfrp5与FEV1/FVC(r=0.466,P<0.001)和FEV1占预计值(r=0.412,P=0.007)正相关,与ln(HOMA-IR)(r=-0.304,P<0.001)、诱导痰TNF-α(r=-0.459,P=0.002)和IL-6(r=-0.517,P<0.001)负相关。

关键数值与推荐

  • 胰岛素抵抗判定采用HOMA-IR≥2.29。
  • BMI、ln(HOMA-IR)和诱导痰IL-6为血清sfrp5的独立相关因素(r²值分别为0.286、0.176、14.69,均P<0.01)。

临床怎么用

  • 对慢阻肺患者可关注胰岛素抵抗状态,其与更重气道炎症和气流受限相关。
  • 血清sfrp5与肺功能及炎症指标相关,可能作为评估慢阻肺合并胰岛素抵抗的线索。

局限性

  • 原文未报告研究类型为横断面或队列,因果推断受限。
  • 原文未报告多因素回归的具体模型与校正变量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the relationship between serum secreted frizzled-related protein 5(sfrp5) levels, insulin resistance, and airway inflammation in patients with chronic obstructive pulmonary disease(COPD). Method: A total of 178 COPD patients visiting our respiratory outpatient clinic from February 2015 to January 2017 were enrolled, and 99 healthy control subjects from the same time period were selected. Serum sfrp5 levels were compared between the 2 groups. Serum sfrp5 and inflammatory cytokines in induced sputum were observed in the 4 subgroups: insulin resistant COPD group [homeostasis model assessment of insulin resistance (HOMA-IR)≥2.29], non-insulin resistant COPD group, non-COPD insulin resistant group, and healthy control group. Results: Serum sfrp5 levels were found to be significantly higher in the COPD group as compared to the healthy control group (t=-14.29, P<0.001). Serum sfrp5 levels in the insulin resistant COPD group [(8±3)ng/ml] were significantly lower than that of the non-insulin resistant COPD group [(10±5)ng/ml], non-COPD insulin resistant group [(13±3)ng/ml], and normal control group [(14±4)ng/ml, F=35.85, P<0.01]. The insulin resistant COPD group had higher levels of In(Homa-IR), as well as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in induced sputum as compared to the non-insulin resistant COPD group, non-COPD insulin resistant group, and healthy control group (F values were 64.968, 41.40, 64.15, respectively, P value <0.01 for all items). The non-insulin resistant COPD group had higher levels of In(HOMA-IR) as well as TNF-α and IL-6 in induced sputum as compared to the non-COPD insulin resistant group and healthy control group. FEV(1)/FVC and FEV(1)% predicted were significantly lower in the insulin resistant COPD group as compared to those of non-insulin resistant COPD group and non-COPD insulin resistant group, and healthy control group (F values were 2.481 and 8.37, respectively, P value<0.05 for all items). FEV(1)/FVC and FEV(1)% predicted were significantly lower in the non-insulin resistant COPD group as compared to those of the healthy control group and non-COPD insulin-resistant group. Serum sfrp5 levels were positively correlated to FEV(1)/FVC and FEV(1) predicted (r values were 0.466 and 0.412, respectively; P values were <0.001 and 0.007, respectively) and inversely correlated to In(HOMA-IR) and TNF-α and IL-6 in induced sputum (r values were -0.304, -0.459, -0.517, respectively; P values were <0.001, 0.002, <0.001, respectively). BMI, ln(HOMA-IR), and IL-6 in induced sputum were independent related factors (r(2) values were 0.286, 0.176, 14.69, respectively; P values were <0.01 for all items) Conclusion: Sfrp5 may be concurrently associated with COPD and insulin resistance; insulin resistance may be associated with airway inflammation and airflow limitation. Sfrp5 may be involved in the development of COPD and may be the key link by which insulin resistance exerts its effects on airway inflammation. 目的: 探讨慢性阻塞性肺疾病(慢阻肺)患者血清分泌型卷曲相关蛋白5(sfrp5)水平与气道炎症和胰岛素抵抗的关系。 方法: 选取2015年2月至2017年1月门诊慢阻肺患者178例,其中男152例,女64例,同期健康体检者纳入为对照组99名,其中男87名,女41名。对比两组血清sfrp5水平,观察患者稳态模型评估的胰岛素抵抗指数(HOMA-IR),分为胰岛素抵抗慢阻肺组(HOMA-IR≥2.29)、非胰岛素抵抗慢阻肺组、单纯性胰岛素抵抗组和正常对照组各亚组的血清sfrp5及诱导痰炎症因子水平。 结果: 慢阻肺组的sfrp5水平显著高于健康对照组(t=-14.29,P<0.001);胰岛素抵抗慢阻肺组sfrp5水平[(8±3)ng/ml]显著低于非胰岛素抵抗慢阻肺组[(10±5)ng/ml]、单纯性胰岛素抵抗组[(13±3)ng/ml]、正常对照组[(14±4)ng/ml,F=35.85,P<0.01]。胰岛素抵抗慢阻肺组的In(HOMA-IR)、诱导痰肿瘤坏死因子-α(TNF-α)、IL-6水平高于非胰岛素抵抗慢阻肺组、单纯胰岛素抵抗组和正常对照组(F值分别为64.968、41.40、64.15,均P<0.01);非胰岛素抵抗慢阻肺组的In(HOMA-IR)、诱导痰TNF-α、IL-6水平显著高于单纯胰岛素抵抗组、正常对照组;胰岛素抵抗慢阻肺组FEV(1)/FVC、FEV(1)占预计值显著低于非胰岛素抵抗慢阻肺组、单纯性胰岛素抵抗组、正常对照组(F值分别为2.481、8.37,均P<0.05);非胰岛素抵抗慢阻肺组的FEV(1)/FVC、FEV(1)占预计值%显著低于正常对照组和单纯性胰岛素抵抗组;血清sfrp5水平与FEV(1)/FVC、FEV(1)占预计值%呈正比(r值分别为0.466、0.412,均P<0.01),与In(HOMA-IR)、诱导痰TNF-α、IL-6呈反比(r值分别为-0.304、-0.459、-0.517,均P<0.01)。体重指数、In(HOMA-IR)和诱导痰IL-6为血清sfrp5的独立相关因素(r(2)值分别为0.286、0.176、14.69,均P<0.01)。 结论: sfrp5可能同时与慢阻肺、胰岛素抵抗有关;胰岛素抵抗可能与气道炎症、气流受限有关;sfrp5可能参与慢阻肺的发生发展,也可能是胰岛素抵抗影响气道炎症的关键环节。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li GY, Yin SJ, Liu Y, et al. [Correlation analysis of serum secreted frizzled-related protein 5 levels with airway inflammation and insulin resistance in chronic obstructive pulmonary disease patients]. Zhonghua Jie He He Hu Xi Za Zhi. 2017. PMID: 29224299. doi:10.3760/cma.j.issn.1001-0939.2017.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。